140472-69-1

Basic information

• Product Name: 3-BROMO-5-HYDROXYBENZOIC ACID
• Synonyms: Benzoic acid, 3-broMo-5-hydroxy-;5-Hydroxy-3-bromobenzoic acid;3-BroMo-5-hydroxybenzoic acid;3-BroMo-5-hydroxybenzoic acid 97%
• CAS NO: 140472-69-1
• Molecular Formula: C₇H₅BrO₃
• Molecular Weight: 217.03
• Product Categories: C7;Carbonyl Compounds;Carboxylic Acids
• Mol File: 140472-69-1.mol
• Article Data: 6

Chemical Properties

• Melting Point: 237-241 °C
• Boiling Point: 388.1 °C at 760 mmHg
• Flash Point: 188.5 °C
• Appearance: /
• Density: 1.861 g/cm³
• Vapor Pressure: 1.02E-06mmHg at 25°C
• Refractive Index: 1.654
• Storage Temp.: Room temperature.
• Solubility: soluble in Methanol
• PKA: 3.69±0.10(Predicted)
• CAS DataBase Reference: 3-BROMO-5-HYDROXYBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-5-HYDROXYBENZOIC ACID(140472-69-1)
• EPA Substance Registry System: 3-BROMO-5-HYDROXYBENZOIC ACID(140472-69-1)

Safety Data

• Hazard Codes: Xn,N
• Statements: 22-50
• Safety Statements: 61
• RIDADR: UN 2811 6.1/PG 3
• WGK Germany: 3
• HazardClass: 9
• PackingGroup: III
• Hazardous Substances Data: 140472-69-1(Hazardous Substances Data)

Usage

Purification Methods

The acid crystallises from H2O (m 238-239o), and with Me2SO4 it yields the 3-methoxy derivative with m 190-191o (from EtOH). [Baddar et al. J Chem Soc 469 1955, Beilstein 10 IV 333.]

InChI:InChI=1/C7H5BrO3/c8-5-1-4(7(10)11)2-6(9)3-5/h1-3,9H,(H,10,11)

Upstream product

• 121-92-6 3-nitrobenzoic acid 
• 6307-83-1 3-bromo-5-nitro-benzoic acid 
• 42237-85-4 3-amino-5-bromobenzoic acid 
• 188815-32-9 3-bromo-5-iodo-benzoic acid 

Downstream Products

• 855198-27-5 3-bromo-5-ethoxybenzoic acid 
• 1140958-45-7 C₁₁H₁₄O₃ 
• 1229442-68-5 ethyl 3-bromo-5-ethoxybenzoate 
• 1217338-29-8 2-(4-fluorophenyl)-5-(3-hydroxy-5-(isobutylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide 
• 1217340-58-3 3-bromo-N-isobutyl-5-isopropoxybenzamide 
• 1217337-94-4 2-(4-fluorophenyl)-5-(3-(isobutylcarbamoyl)-5-isopropoxyphenyl)-N-methylbenzofuran-3-carboxamide 
• 192810-12-1 3-bromo-5-hydroxy-benzoic acid methyl ester 
• 1162261-25-7 3-bromo-5-hydroxy-N,N-dimethyl-benzamide 
• 1163141-57-8 3-cyano-5-hydroxy-benzoic acid 
• 870673-42-0 diethyl 5,5'-[benzene-1,4-diyl-bis(ethyne-2,1-diyl)]bis(3-dodecyloxybenzoate) 
• 870673-40-8 triethyl 5,5',5''-[benzene-1,3,5-triyl-tris(ethyne-2,1-diyl)]tris(3-hydroxybenzoate) 
• 870673-39-5 diethyl 5,5'-[tolan-4,4'-diyl-bis(ethyne-2,1-diyl)]bis(3-hydroxybenzoate) 
• 870673-38-4 diethyl 5,5'-[benzene-1,4-diyl-bis(ethyne-2,1-diyl)]bis(3-hydroxybenzoate) 
• 870673-36-2 ethyl 3-hydroxy-5-[2-(trimethylsilyl)ethynyl]benzoate 

Relevant articles and documents

Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships

Cyclic nucleotide cAMP is a ubiquitous secondary messenger involved in a plethora of cellular responses to biological agents involving activation of adenylyl cyclase. Its intracellular levels are tightly controlled by a family of cyclic nucleotide degrading enzymes, the PDEs. In recent years, cyclic nucleotide phosphodiesterase type 4 (PDE4) has aroused scientific attention as a suitable target for anti-inflammatory therapy in respiratory diseases, particularly in the management of asthma and COPD. Here we describe our efforts to discover novel, highly potent inhaled inhibitors of PDE4. Through structure based design, with the inclusion of a variety of functional groups and physicochemical profiles in order to occupy the solvent-filled pocket of the PDE4 enzyme, we modified the structure of our oral PDE4 inhibitors to reach compounds down to picomolar enzymatic potencies while at the same time tackling successfully an uncovered selectivity issue with the adenosine receptors. In vitro potencies were demonstrated in a rat lung neutrophilia model by administration of a suspension with a Penn-Century MicroSprayer Aerosolizer.

(3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors

New (3-oxo)pyridazin-4-ylurea derivatives having the chemcial structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of the phosphodiesterase IV (PDE4).

LEUKOTRIENE B4 INHIBITORS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, COPD.